Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.

Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.

Abstract: The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.

Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.

Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.

Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.

Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.

Abstract: Provided are a peptide with a cytoprotective effect against environmental pollutants and a use thereof. The peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, or 3 directly binds to 2,3,7,8-tetrachlorodibenzo-p-dioxin (hereinafter, referred to as TCDD), known as being the most toxic among the class of dioxins, to prevent dermal penetration and the activation mechanism of AhR by TCDD and polycyclic aromatic hydrocarbons contained in fine dust. Such a direct cytoprotective effect against environmental pollutants is distinguished from preexisting methods that are configured to indirectly block opportunities to contact these materials or to reduce toxicity through barrier reinforcement.

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

Abstract: The present disclosure provides peptoid-based chelating ligands, corresponding cyclic peptoids, and methods of making thereof. Functional groups may be tailored for high metal binding affinity and selectivity. The side chains of a cyclic peptoid according to the present disclosure may be selected based on, for example, high affinity for actinide or other metal ions, selectivity for actinide or other metal ions, the ability to recover a metal once it is bound to the peptoid, and whether the overall peptoid should be hydrophobic or hydrophilic. Unlike siderophores, peptoid-based chelating ligands of the present disclosure are not readily hydrolyzed under physiological conditions. Therefore, peptoid-based chelating ligands may be, for example, used to treat actinide (e.g., iron and lead) poisoning in vivo. Moreover, peptoid-based chelating ligands of the present disclosure may be used for medical imaging, chelation therapy, drug delivery, and separation technologies, for example.

Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.

Abstract: Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.

Abstract: Compositions are disclosed herein comprising a graft copolymer that comprises: (i) a backbone comprising an alpha-1,3-glucan ether or ester compound, and (ii) one or more alpha-1,3-glucan side chains comprising at least about 50% alpha-1,3 glycosidic linkages. Further disclosed are reactions for producing such graft copolymers, as well as their use in various applications.

Abstract: Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex. In certain aspects, the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking. In certain aspects, the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran. In exemplary implementations, the functionalized dextran is an amine dextran. In further embodiments, one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.

Abstract: Ethylene-based polymers are characterized by a melt index less than 1 g/10 min, a density from 0.94 to 0.965 g/cm3, a Mw from 100,000 to 250,000 g/mol, a relaxation time from 0.5 to 3 sec, and an average number of long chain branches (LCBs) per 1,000,000 total carbon atoms in a molecular weight range of 300,000 to 900,000 g/mol that is greater than that in a molecular weight range of 1,000,000 to 2,000,000 g/mol, or an average number of LCBs per 1,000,000 total carbon atoms in a molecular weight range of 1,000,000 to 2,000,000 g/mol of less than or equal to about 5 and a maximum ratio of ?E/3? at an extensional rate of 0.1 sec?1 from 1.2 to 10. These polymers have substantially no long chain branching in the high molecular weight fraction of the polymer, but instead have significant long chain branching in a lower molecular weight fraction, such that polymer melt strength and parison stability are maintained for the fabrication of blow molded products and other articles of manufacture.

Abstract: Disclosed herein are oligomerization processes in which ethylene and a catalyst system are first combined for a suitable residence time in an activation vessel, prior to introduction into a reaction zone to oligomerize ethylene to form a desired oligomer product, such as 1-hexene and/or 1-octene. Related oligomerization reaction systems that include the activation vessel also are disclosed. In these oligomerization processes and reaction systems, the catalyst system can be fully activated as it leaves the activation vessel and enters the reaction zone, thus providing greater catalyst utilization and less catalyst waste.

Abstract: A method of making a pyranine monomer composition comprises the step of reacting pyranine with a functionalizing agent that functionalizes the pyranine molecule with a polymerizable functional group to provide a composition of functionalized pyranine monomers, said functionalization reaction taking place in an aqueous reaction medium, and in the presence of a molar excess of said functionalizing agent, such that the functionalization reaction product is a monomer composition substantially free of unfunctionalized pyranine compound. The pyranine monomer compositions made by the method can be used to make fluorescent tagged water soluble polymer compositions that advantageously are substantially free of unpolymerized pyranine. The fluorescent tagged water soluble polymer compositions can be used in a method of inhibiting scale in industrial water systems.

Abstract: A test cell useful for determining the photosensitivity of a photopolymerizable material, includes a support plate having a top surface portion, a bottom surface portion, and an opening extending therebetween, a light-transmissive base member removably or permanently connected to said bottom surface portion to form with said opening a well, into which well photopolymerizable material can be deposited, and a sensor comprising a thermal sensor, strain sensor, or combination thereof operatively associated with said light-transmissive base member.

Abstract: Object: To provide a method for manufacturing a polymer, which is a method for forming a polymer having a homogeneous copolymer composition and a narrow molecular weight distribution. Resolution Means: A method for manufacturing a polymer using a microreactor including a flow path capable of mixing a plurality of liquids to perform radical polymerization of a monomer component containing two or more types of monomers in the presence of a polymerization initiator; wherein the microreactor includes a first inlet port configured to feed the monomer component and an additional inlet port located downstream of the first inlet port; and the method includes feeding the monomer component through the first inlet port and the additional inlet port.

Abstract: The invention provides a method for preparation of homopolymers and non-homopolymers comprising polymerizing in an aqueous medium a monomer comprising at least one acryloyl moiety and at least one functionalized or unfunctionalized lactam moiety, and optionally at least one hydrophilic or hydrophobic comonomer, in the presence of at least one chain transfer agent and at least one non-radiation initiator. Exemplary diblock polymers prepared by the method have the structure: where subscripts x, y, and z and variables R, R8, R9 and R10 are described herein.

Abstract: The present invention relates to a process for producing a heterophasic propylene copolymer (RAHECO) having a xylene cold soluble fraction (XCS) determined according to ISO 16152 (25° C.) of more than 30 wt.-%, a heterophasic propylene copolymer (RAHECO) produced by the process as well as an article, preferably a film, a flexible tube or cable insulation, comprising the heterophasic propylene copolymer (RAHECO).

Abstract: A compound of formula (1) as drawn herein, wherein M is a Group 4 metal and each R independently is a silicon-free organic solubilizing group. A method of synthesizing the compound (1). A solution of compound (1) in alkane solvent. A catalyst system comprising or made from compound (1) and an activator. A method of polymerizing an olefin monomer with the catalyst system.

Abstract: A process to produce a branched ethylene-?-olefin diene elastomer comprising combining a catalyst precursor and an activator with a feed comprising ethylene, C3 to C12 ?-olefins, and a dual-polymerizable diene to obtain a branched ethylene-?-olefin diene elastomer; where the catalyst precursor is selected from pyridyldiamide and quinolinyldiamido transition metal complexes. The branched ethylene-?-olefin diene elastomer may comprise within a range from 40 to 80 wt % of ethylene-derived units by weight of the branched ethylene-?-olefin diene elastomer, and 0.1 to 2 wt % of singly-polymerizable diene derived units, 0.1 to 2 wt % of singly-polymerizable diene derived units, and the remainder comprising C3 to C12 ?-olefin derived units, wherein the branched ethylene-?-olefin diene elastomer has a weight average molecular weight (Mw) within a range from 100 kg/mole to 300 kg/mole, an average branching index (g?avg) of 0.9 or more, and a branching index at very high Mw (g?1000) of less than 0.9.

Abstract: The present invention pertains to a melt-processible fluoropolymer, to a composition comprising the melt-processible fluoropolymer, to a process for manufacturing the melt-processible fluoropolymer and to uses of the melt-processible fluoropolymer in various applications.

Abstract: A curable composition for an electronic device, includes a curable material; and an oxide-containing complex; wherein the oxide-containing complex includes i) an oxide core and ii) an organic group chemically bound to an atom on a surface of the oxide core, the organic group includes a) a curable group reactable with the curable material and b) a linking group linking the atom on a surface of the oxide core to the curable group, and the oxide core includes an aluminum oxide, a silicon oxide, or a combination thereof.

Abstract: The invention provides a method for producing a polymer used as a base film for cell culture which comprises (i) preparing a mixture containing (a) a monomer of formula (I): wherein Ua1 and Ua2 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, Ra1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, and Ra2 represents a linear or branched alkylene group having 1 to 5 carbon atoms, (b) a radical polymerization initiator, and (c) an organic solvent, and (ii) preparing a polymer by raising a temperature of the mixture under stirring to polymerize the monomer. The invention also provides methods of producing a base film for cell culture and a cell culture container.

Abstract: A system for continuously treating recycled polystyrene material includes a hopper/densifier configured to feed recycled polystyrene material into the system. An extruder can turn the recycled polystyrene material into a molten material. In some embodiments, the extruder uses thermal fluids, electric heaters, and/or a separate heater. Solvents, such as toluene, xylenes, cymenes, and/or terpinenes can aid in generating the molten material. The molten material can be depolymerized in a reactor and a catalyst can be used to aid the depolymerizing. In certain embodiments, the catalyst is contained in a permeable container. In some embodiments, copolymers/monomers are grafted onto the depolymerized material. The depolymerized molten material can be cooled via a heat exchanger. The product can be isolated by extraction, distillation, and/or separation. In some embodiments, the product is treated through filtration and absorption media. In some embodiments, multiple reactors are used.

Abstract: Provided are reactive silicon group-containing polymers and a curable composition containing said polymers. The curable composition provides a cured product having a low modulus, flexibility, excellent tensile strength, tensile elongation, and tear strength. The curable composition can also exhibit excellent rapid curing properties even when a low-activity catalyst has been added. In the reactive silicon group-containing polymer, a reactive silicon group, indicated by general formula (1): (—Si(R1)3-a(X)a), is bonded to the molecular chain of the polymer and an atom adjacent to the reactive silicon group has an unsaturated bond. In general formula (1), each R1 can independently indicate a C1-20 hydrocarbon group, and the R1 hydrocarbon groups can be substituted and a hetero-containing group can be used. X can be a hydroxyl group or a hydrolyzable group, and a is 1, 2, or 3.

Abstract: A block copolymer of polyamide acid includes a first polyamide acid and a second polyamide acid alternately connected. The first polyamide acid is made by first dianhydride monomers and second diamine monomers. The second polyamide acid is made by second dianhydride monomers and first diamine monomers. Each first dianhydride monomer is or comprises a liquid crystal structure. Each second dianhydride monomer and each second diamine monomer respectively include a first flexible structure. Each first diamine monomer includes a liquid crystal structure. Each liquid crystal structure includes a cyclic group selected from a chemical structural formula of and intermediate groups selected from a chemical structural formula of Each flexible structure includes a group selected from a group consist of ether bond, ketone group, sulphone group, aliphatic hydrocarbon group, and any combination thereof.

Abstract: Branched block copolymers, derived from alkenyl aromatic hydrocarbon-1,3-diene monomer system, and branched polyisoprene homopolymers, derived from isoprene, are obtained by polymerization in the presence of an anionic initiator; at a temperature from 0° C. to 100° C.; followed by coupling with a multifunctional coupling agent of formula (R1O)3Si—Y—Si(OR2)3, wherein R1 and R2 are independently C1-C6 alkyl groups; and Y is a C2-C8 alkylene group. The polymers thus obtained can be used in many applications, including rubber cements having high solids content and low zero shear viscosities, and for producing aqueous latices therefrom.

Abstract: The present invention relates to a catalyst for olefin polymerization. Specifically, the present invention relates to a hybrid catalyst comprising different transition metal compounds and capable of preparing a polyolefin, particularly a linear low-density polyethylene, which has excellent processability, impact strength, and haze.

Abstract: This disclosure provides new methods for the design and development of ethylene polymerization catalysts, including Group 4 metallocene catalysts such as zirconocenes, which are based on an improved ability to adjust co-monomer incorporation into the polymer. Computational analyses with and without dispersion corrections revealed that designing catalyst scaffolds which induce stabilizing non-covalent dispersion type interactions with incoming ?-olefin co-monomers can be used to modulate co-monomer selectivity into the polyethylene chain. Demonstrated herein is a lack of correlation of computed ??G‡ values against experimental ??G‡ values when the dispersion correction (D3BJ) was disabled, and B3LYP was used in the absence of Grimme's D3 dispersion and Becke-Johnson (BJ) dampening, but a correlation of computed against experimental ??G‡ with B3LYP+D3BJ, which are used to design new catalyst scaffolds.

Abstract: The present invention is directed to a method for preparing a thermoplastic polyurethane having a low glass transition temperature. The process according to the present invention comprises the steps of providing at least one polyol composition (P) comprising a poly-?-caprolactone polyol (P1), and a second polyol (P2) which is different from the first polyol (P1), and reacting the at least one polyol composition (P) with at least one polyisocyanate (P1) and at least one low molecular weight diol (CE) optionally in the presence of at least one catalyst (CA) and/or at least one additive (AD) to obtain a thermoplastic polyurethane. The present invention is also directed to the thermoplastic polyurethane obtained according to the process of the present invention and the use thereof in extruded articles and injection molded articles.

Abstract: There is provided herein a silylated polyurethane composition, a process of preparing a silylated polyurethane polymer, and an adhesive, sealant or coating containing a silylated polyurethane made therewith.

Abstract: Provided are a composition capable of forming a cured product with excellent hardness, scratch resistance, chemical resistance, and flexibility; and a polyisocyanate compound that can be used as a curing agent for the composition. The polyisocyanate compound is represented by Formula (1), wherein R1 to R3 are identical or different and are a group represented by Formula (1a), wherein L1 and L2 are identical or different and represent an alkylene group having from 1 to 10 carbons, m represents a number of 0 or greater, L3 represents a divalent hydrocarbon group having from 4 to 18 carbons, and X represents an isocyanate group or a blocked isocyanate group blocked with a blocking agent, where m is not simultaneously 0 for R1 to R3, and the bond with the wavy line bonds to a nitrogen atom in Formula (1). In addition, the composition contains a polyisocyanate compound and a polyacrylic polyol.

Abstract: Provided are a liquid crystal polymer film (LCP film) and a laminate comprising the same. The LCP film has a first surface and a second surface opposite each other, and the first surface has an arithmetical mean height of a surface (Sa) less than 0.32 ?m. The LCP film with proper Sa is suitable to be stacked with a metal foil, such that a laminate comprising the LCP film can have an advantage of low insertion loss.

Abstract: The invention relates to a thermoplastic polymer comprising at least one 1,4:3,6-dianhydrohexitol unit (A), at least one alicyclic diol unit (B) other than the 1,4:3,6-dianhydrohexitol units (A) and at least one high-viscosity terephthalic acid unit (C).

Abstract: Provided is a polycarbonate resin composition and a molded product comprising same. The polycarbonate resin composition comprises a linear polycarbonate resin, a branched polycarbonate resin, a fluorinated sulfonate-based metal salt, a phenyl methyl silicone oil, and a phenyl methyl silicone resin. The linear polycarbonate resin and branched polycarbonate resin include a repeating unit of the following Chemical Formula 1: wherein in Chemical Formula 1: R1 to R4 are each independently hydrogen, C1-10 alkyl, C1-10 alkoxy, or halogen; and Z is C1-10 alkylene unsubstituted or substituted with phenyl, C3-15 cycloalkylene unsubstituted or substituted with C1-10 alkyl, O, S, SO, SO2, or CO.

Abstract: In an embodiment, a reactor for carrying out a melt transesterification reaction at a reactor temperature of 160 to 300° C. and a reactor pressure of 5 to 200 mbar, comprises a cylindrical tank comprising a top, a side, and a bottom, wherein the bottom is convex, extending away from the top; a stirring shaft disposed within the cylindrical tank along an axis thereof so that it is rotatable from outside of the cylindrical tank; an impeller extending from the stirring shaft in the cylindrical tank and comprising a plurality of blades; a reactant solution inlet; a reaction solution outlet; and an externally located heat exchanger in fluid communication with the cylindrical tank via a recirculation stream and a heated stream. The reactor can be used for the polymerization of a polycarbonate oligomer.

Abstract: The present disclosure relates to a method for preparing a polyalkylene carbonate. More specifically, provided is a method for preparing a polyalkylene carbonate in which after polymerization of polyalkylene carbonate, a mixture from which unreacted carbon dioxide and residual catalyst have been removed is charged into a stripper to remove the unreacted epoxide compound, and then heat-exchanged before removing the solvent to increase the temperature of the mixture stream to the maximum level, which is subjected to a heating step, following by a solvent removal step, whereby the amount of steam required in the heating step is reduced, side reactions due to unreacted epoxide compounds are prevented, and steam energy can be reduced in the solvent removal step.

Abstract: Provided is a novel polyoxyalkylene compound which contains, at a molecular chain terminal, at least one reactive silicon-containing group represented by formula (1) per molecule and which has a main chain that is a polyoxyalkylene polymer. Also provided are: a process for producing the novel polyoxyalkylene compound; a room-temperature-curable composition which includes the compound as a main component and can contain any of various crosslinking agents; a sealing material; and an article. (In formula (1), R1 and R2 are each a monovalent hydrocarbon group, a hydrogen atom, or a triorganosiloxy group; n is 2 or larger; m is 1 or larger; and the broken line is a linking bond).

Abstract: Methods for synthesizing a polyamide having the optical absorber in the backbone of the polyamide may comprise: polymerizing polyamide monomers in the presence of an optical absorber selected from the group consisting of a polyamine optical absorber, a polyacid optical absorber, an amino acid optical absorber, and any combination thereof to yield the polyamide having the optical absorber in the backbone of the polyamide. Said polyamides having the optical absorber in the backbone of the polyamide may be useful in producing objects by methods that include melt extrusion, injection molding, compression molding, melt spinning, melt emulsification, spray drying, cryogenic milling, freeze drying polymer dispersions, and precipitation of polymer dispersions.